Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data.

Abstract

KEY POINTS Biologics represent a large segment of drug spending in Canada: although they constituted just 1.5% of prescription volumes, biologics accounted for 27.3% of expenditures in 2018.[1][1] As of 2018, the price of biologics in Canada, including spending per capita, was second only to that in